Search Within

Ross Levine

Formats
  1. Journal Article (391)
  2. Meeting Abstract (348)
  3. Editorial (14)
  4. Review (13)
  5. Research Letter (11)
  6. Book Section (3)
  7. Conference Paper (2)
  8. Guidelines (2)
  9. Book Whole (1)
Groups
  1. Adult Leukemia (785)
  2. Center for Hematologic Malignancies (785)
  3. Center for Molecular Imaging and Biotechnology (CMIB) (785)
  4. Department of Medicine (785)
  5. Executive Committee, Center for Hematologic Malignancies (785)
  6. GSK Faculty (785)

More Groups

People
  1. Omar Abdel-Wahab (168)
  2. Martin Tallman (131)
  3. Raajit Rampal (87)
  4. Eytan Stein (75)
  5. Maria Arcila (60)
  6. Jay Patel (52)

More People

Years
  1. 2025 (12)
  2. 2024 (36)
  3. 2023 (46)
  4. 2022 (41)
  5. 2021 (44)
  6. 2020 (58)

More Years

Publications
  1. Blood (293)
  2. Leukemia (34)
  3. Cancer Research (27)
  4. Haematologica (24)
  5. Blood Advances (21)
  6. Cancer Cell (21)

More Publications

Publishers
  1. American Society of Hematology (316)
  2. Nature Publishing Group (109)
  3. American Association for Cancer Research (68)
  4. Cell Press (48)
  5. Ferrata Storti Foundation (24)
  6. American Society of Clinical Oncology (23)

More Publishers

Results (785)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Transcriptional activation of regenerative hematopoiesis via microenvironmental sensing
    Journal Article

    Itkin, T.; Houghton, S.; Schreiner, R.; Lin, Y.; Badwe, C. R.; Voisin, V.; Murison, A.; Seyedhassantehrani, N.; Kaufmann, K. B.; Garcia-Prat, L.; more...
    Nature Immunology (2025)

    Fulltext@MSK | Save
  • Exercise and Nutrition to Improve Cancer Treatment-Related Outcomes (ENICTO)
    Editorial

    Schmitz, K. H.; Brown, J. C.; Irwin, M. L.; Robien, K.; Scott, J. M.; Berger, N. A.; Caan, B.; Cercek, A.; Crane, T. E.; Evans, S. R.; more...
    JNCI: Journal of the National Cancer Institute (2025)

    Fulltext@MSK | Save
  • A multi-site break through cancer trial: Phase II study investigating dual inhibition of BCL2 and menin in AML MRD using the combination of venetoclax and revumenib (trial in progress)
    Meeting Abstract

    Issa, G. C.; Ambinder, A. J.; Xiao, W.; Manalis, S.; Shalek, A. K.; Gondek, L. P.; Kentsis, A.; Short, N. J.; Daver, N.; Ning, J.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Demographics, characteristics, survival and outcomes in older, untreated, acute myeloid leukemia patients with NPM1 mutations or KMT2A rearrangements from the Beat AML Master Clinical Trial
    Meeting Abstract

    Borate, U.; Li Welkie, R.; Huang, Y.; Swords, R. T.; Traer, E.; Stein, E. M.; Lin, T. L.; Madanat, Y. F.; Patel, P. A.; Collins, R. H.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • TMPRSS6 antisense oligonucleotide therapy reverses inflammation in Jak2(V617F) mutant mice
    Meeting Abstract

    Levy, M.; Li, H.; Dunbar, A.; Huang, Z.; Park, Y.; Lu, M.; Phattalung, P. N.; Planoutene, M.; Casu, C.; Rivella, S.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • A phase 1, open-label, dose escalation and dose expansion, multicenter clinical trial to evaluate the safety, pharmacokinetics, pharmacodynamics, and preliminary efficacy of lomonitinib (ZE46-0134) in adults with FLT3-mutated relapsed or refractory acute myeloid leukemia
    Meeting Abstract

    Lin, T. L.; Koenig, K. L.; Swords, R. T.; Stein, E. M.; Baer, M. R.; Stock, W.; Madanat, Y. F.; Olin, R.; Blum, W.; Schiller, G. J.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • A randomized phase 2 trial of 28-day (Arm A) versus 14-day (Arm B) schedule of venetoclax + azacitidine in newly diagnosed acute myeloid leukemia patients ≥ 60 years
    Meeting Abstract

    Borate, U.; Huang, Y.; Zeidner, J. F.; Swords, R. T.; Koenig, K. L.; Stein, E. M.; Baer, M. R.; Stock, W.; Madanat, Y. F.; Olin, R.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Combined human and in vivo analyses implicate the critical importance of acute myeloid leukemia associated CD8 T cells and identifies their molecular dysfunction
    Meeting Abstract

    Chu, Y. E.; Cottam, M. A.; Potts, C. R.; Dickerson, K. M.; Jenkins, M. T.; Cartailler, J. A.; Lu, R.; Lee, S. C.; Levine, R. L.; Bowman, R. L.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Outcomes and survival in newly diagnosed, older, acute myeloid leukemia patients from the beat AML master trial in the venetoclax/azacitidine age
    Meeting Abstract

    Borate, U.; Huang, Y.; Li Welkie, R.; Swords, R. T.; Traer, E.; Stein, E. M.; Lin, T. L.; Madanat, Y. F.; Patel, P. A.; Collins, R. H.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • IDH2 mutation is associated with favorable outcome among older adults with newly diagnosed acute myeloid leukemia treated with lower-intensity therapy
    Meeting Abstract

    Hoff, F. W.; Huang, Y.; Li Welkie, R.; Swords, R. T.; Traer, E.; Stein, E. M.; Lin, T. L.; Patel, P. A.; Collins, R. H.; Baer, M. R.; more...
    Blood (2024)

    Fulltext@MSK | Save